CRISPR Therapeutics and Vertex Pharmaceuticals (NASDAQ:VRTX) are awaiting a review from the U.S. Food and Drug Administration (FDA) for their joint product, exagamglogene...
Bank of America reiterated their Buy rating on Salesforce (NYSE:CRM) with a 12-month price target of $280.00 after attending the software company’s Dreamforce conference this...
Vertex Pharmaceuticals Inc's (NASDAQ: VRTX) Q2 sales increased 14% to $2.49 billion, beating the consensus of $2.41 billion. The increase was driven by the strong uptake of...
Investing.com - Vertex (NASDAQ: VRTX) reported second quarter EPS of $3.89, $0.03 better than the analyst estimate of $3.86. Revenue for the quarter came in at $2.49B versus the...
Goldman Sachs analysts published today a new investment list that consists of 22 stocks highlighted by the broker's research analysts. It includes fundamental Buy-rated U.S. stocks...
By Davit KirakosyanHere is your Pro Recap of the biggest analyst picks and cuts you may have missed since Friday: upgrades at RingCentral, Dollar General, UWM, and Hamilton Lane;...
Investing.com - Vertex (NASDAQ: VRTX) reported first quarter EPS of $3.05, $0.02 better than the analyst estimate of $3.03. Revenue for the quarter came in at $2.37B versus the...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a...
The U.S. biotech sector, which has been underperforming this year, is displaying signs of a revival, with the iShares Biotechnology ETF (NASDAQ: IBB) staging a mini-rally in the...